Results 31 to 40 of about 15,994,939 (300)

A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers

open access: yesNature Communications, 2022
Antigen escape represents a potential drawback of chimeric antigen receptor T cell (CAR-T) therapy targeting a single tumor-associated antigen. To reduce the risk of antigen escape, here the authors report the design and characterization of a BAFF ligand
Derek P. Wong   +12 more
doaj   +1 more source

Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy

open access: yesClinical Cancer Research, 2016
Chimeric antigen receptors (CAR) are engineered fusion proteins constructed from antigen recognition, signaling, and costimulatory domains that can be expressed in cytotoxic T cells with the purpose of reprograming the T cells to specifically target ...
Marcela V. Maus, C. June
semanticscholar   +1 more source

Discovering immunoreceptor coupling and organization motifs

open access: yesFrontiers in Immunology, 2023
The recently determined cryo-EM structures of the T cell antigen receptor (TCR) and B cell antigen receptor (BCR) show in molecular details the interactions of the ligand-binding part with the signaling subunits but they do not reveal the signaling ...
Michael Reth, Michael Reth
doaj   +1 more source

Modulation of antigen-specific T-cells as immune therapy for chronic infectious diseases and cancer [PDF]

open access: yes, 2014
Copyright: © 2014 Li, Symonds, Miao, Sanderson and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).
Miao, T   +13 more
core   +1 more source

Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects

open access: yesFrontiers in Immunology, 2022
To redirect T cells against tumor cells, T cells can be engineered ex vivo to express cancer-antigen specific T cell receptors (TCRs), generating products known as TCR-engineered T cells (TCR T).
Paul Shafer   +7 more
doaj   +1 more source

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

open access: yesNature Medicine, 2018
Tolerance to self-antigens prevents the elimination of cancer by the immune system1,2. We used synthetic chimeric antigen receptors (CARs) to overcome immunological tolerance and mediate tumor rejection in patients with chronic lymphocytic leukemia (CLL).
J. Fraietta   +36 more
semanticscholar   +1 more source

Human T cell responses to peptides of the Mycobacterium leprae 45-kD serine-rich antigen. [PDF]

open access: yes, 2002
In order to identify T cell epitopes within the Mycobacterium leprae 45-kD serine-rich antigen, we analysed responses to overlapping 17-mer peptides encompassing the whole antigen in non-exposed UK controls, Pakistani leprosy patients and tuberculosis ...
Zafar, S   +9 more
core   +1 more source

Dual function of the NK cell receptor 2B4 (CD244) in the regulation of HCV-specific CD8+ T cells [PDF]

open access: yes, 2011
The outcome of viral infections is dependent on the function of CD8+ T cells which are tightly regulated by costimulatory molecules. The NK cell receptor 2B4 (CD244) is a transmembrane protein belonging to the Ig superfamily which can also be expressed ...
Lunemann, Sebastian   +35 more
core   +2 more sources

Induction of IgG3 to LPS via Toll-like receptor 4 co-stimulation. [PDF]

open access: yesPLoS ONE, 2008
B-cells integrate antigen-specific signals transduced via the B-cell receptor (BCR) and antigen non-specific co-stimulatory signals provided by cytokines and CD40 ligation in order to produce IgG antibodies.
Francisco J Quintana   +3 more
doaj   +1 more source

Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors

open access: yesTIPS - Trends in Pharmacological Sciences, 2015
The tumor-killing properties of T cells provide tremendous opportunities to treat cancer. Adoptive T cell therapies have begun to harness this potential by endowing a functionally diverse repertoire of T cells with genetically modified, tumor-specific ...
D. Harris, D. Kranz
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy